Wednesday 14 October 2026
Export CVS’s income statement to Excel — free account
CVS Health Corporation
CVS Healthcare Healthcare Plans
CVS Health Corporation’s revenue for fiscal 2025 (year ended December 2025) was $402.1 billion, up 7.85% from fiscal 2024. In the quarter to June 2026, revenue grew 7.26%, EPS grew 187.7%, free cash flow grew 338.3% and total debt fell 7.64%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten.
87.65
0.09
−0.10%
Follow CVS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
27.01 | 31.09 | 56.28 | 188.48 |
+8 more quarters Free account |
P/S ratio |
0.32 | 0.22 | 0.25 | 0.24 | |
P/FCF ratio |
11.25 | 12.37 | 12.88 | 15.20 | |
P/Operating CF |
20.85 | 21.52 | 29.66 | 120.19 | |
P/B ratio |
1.66 | 1.18 | 1.33 | 1.31 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.43 | 0.35 | 0.38 | 0.38 | |
EV/EBITDA |
9.70 | 8.78 | 10.31 | 9.86 | |
EV/Operating CF |
12.16 | 13.81 | 14.52 | 16.50 | |
EV/FCF |
15.29 | 19.30 | 19.79 | 23.88 | |
Quick Ratio |
0.62 | 0.61 | 0.57 | 0.59 | |
Current Ratio |
0.87 | 0.87 | 0.84 | 0.83 | |
Net Debt/EBITDA |
8.14 | 8.85 | 16.56 | 14.95 | |
Debt/Assets |
24.20% | 24.95% | 25.47% | 25.78% | |
Debt/Equity |
0.77 | 0.81 | 0.86 | 0.90 | |
Asset Turnover |
1.62 | 1.60 | 1.59 | 1.55 | |
Operating CF/Net income |
2.13 | 1.44 | 1.15 | (0.20) | |
Capex/Depreciation |
(0.61) | (0.76) | (0.68) | (0.10) | |
Interest Coverage |
6.21 | 6.05 | 2.68 | (4.09) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.43 | 0.44 | 0.44 | 0.44 | |
Share Based Compensation of Revenue |
0.17% | 0.26% | 0.13% | 0.13% | |
Graham Net Nets |
(0.74) | (1.10) | (1.03) | (1.10) | |
Graham Number |
73.37 | 56.30 | 43.45 | 22.77 | |
Earnings Yield |
3.70% | 3.22% | 1.78% | 0.53% | |
Free Cash Flow Yield |
8.89% | 8.09% | 7.76% | 6.58% | |
Revenue per Share |
82.95 | 78.89 | 83.42 | 81.06 | |
Operating CF per Share |
4.96 | 3.34 | 2.68 | 0.63 | |
Capex per Share |
(0.54) | (0.67) | (0.62) | (0.55) | |
Free Cash Flow per Share |
4.42 | 2.67 | 2.06 | 0.08 | |
Cash per Share |
10.91 | 9.27 | 8.36 | 8.85 | |
Shareholders Equity per Share |
62.47 | 60.99 | 59.50 | 57.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
62.47 | 60.99 | 59.50 | 57.61 | |
Free Cash Flow |
5,654.00 | 3,400.00 | 2,606.00 | 98.00 | |
Working Capital |
(11,695.00) | (11,589.00) | (13,978.00) | (15,586.00) | |
Capital Expenditures |
(691.00) | (849.00) | (784.00) | (698.00) | |
Net Current Asset Value |
(98,523.00) | (100,520.00) | (103,442.00) | (105,108.00) | |
EV/EBIT |
21.69 | 23.92 | 33.16 | 30.57 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
15.96 | 15.32 | 21.58 | 19.46 | |
| Other line items | |||||
Average Receivables |
40,480.00 | 40,308.50 | 38,124.00 | 40,018.00 | |
Average Payables |
17,212.50 | 16,728.00 | 16,766.50 | 16,738.50 | |
Average Inventory |
17,534.50 | 17,577.50 | 18,676.50 | 18,305.50 | |
Average Assets |
256,055.50 | 254,279.50 | 253,376.50 | 253,877.00 | |
Average Common Equity |
78,725.00 | 77,373.50 | 75,556.00 | 74,108.00 |
Columns are period end dates